Filing Flows › Orthopediatrics (KIDS) › Guidance & outlook
Orthopediatrics (KIDS) guidance and outlook
Orthopediatrics (KIDS) raised its guidance on Oct 27, 2026: Revenue $270M–$273M for FY2026; Revenue +14% to +16% for FY2026; EBITDA $25.0M for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $270M–$273M | raised |
| Revenue | FY2026 | +14% to +16% | raised |
| EBITDA | FY2026 | $25.0M | reaffirmed |
From the earnings release filed Oct 27, 2026 (8-K on EDGAR).
Orthopediatrics' latest quarter
Orthopediatrics, Q3 2026: revenue $72.7M (+19% year over year), operating margin -5.8%, net loss $5.9M, operating cash flow $4.5M. The chart follows the revenue to costs, profit and cash.
Questions
Did Orthopediatrics raise or lower its guidance?
Orthopediatrics (KIDS) raised its guidance on Oct 27, 2026: Revenue $270M–$273M for FY2026; Revenue +14% to +16% for FY2026; EBITDA $25.0M for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.